NCT06925477Enrolling by invitation
Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT
Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) in Reducing Intraocular Pressure in Open-Angle Glaucoma
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
This study compares two laser treatments for open-angle glaucoma: Selective Laser Trabeculoplasty (SLT) and Direct Selective Laser Trabeculoplasty (DSLT). SLT is a widely used procedure that requires a manual technique with a goniolens, while DSLT is a new, automated, non-contact method using the Eagle system. The study will evaluate whether DSLT is as effective as SLT in reducing intraocular pressure (IOP). Participants will be randomly assigned to receive either treatment and will be monitored over 12 months to assess changes in IOP, medication use, and safety outcomes. The goal is to determine if the simpler DSLT procedure can provide similar results to SLT, potentially improving patient comfort and access to glaucoma care.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- First submitted
- 6 Apr 2025
- Start date
- 7 Aug 2025
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Medical University of South Carolina
- Diseases
- Glaucoma
- NCT number
- NCT06925477
What you commit to
- Study type: Interventional
- Planned participants: 51
- From 7 Aug 2025 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any intraocular surgical procedure within the past 6 months in either eye
Lab values
- Any prior laser trabeculoplasty, including ALT, MLT and SLT.
Other
- Advanced POAG in either eye
- Glaucoma other than OAG (including pigmentary and pseudoexfoliation glaucoma) in either eye
- Mean IOP \> 35 mmHg at either the screening or baseline visit in either eye
- Narrow or closed angle (Shaffer Grade 0, 1, or 2) in either eye
- Contraindications to SLT, brimonidine, apraclonidine, or any other study intervention
- Any corneal pathology that would preclude accurate assessment of IOP by Goldmann tonometry in either eye
- Inability to attend all scheduled study visits
- Pregnancy or plan to become pregnant in the next 1 year
Who the study is looking for
- Age ≥18 years.
- Diagnosed with OAG (including exfoliative/pigmentary glaucoma) or OHT.
- Gonioscopically visible scleral spur for 360 degrees.
- Ability to provide informed consent.
- In good health, without prior laser trabeculoplasty, with decision to treat made by an ophthalmologist on the basis of risk profile, patient preference, or both.
- Each eye with one of the following qualifying diagnoses (diagnoses may differ between eyes):
- High-risk ocular hypertension (OHT): IOP \> 21 mmHg without glaucomatous optic neuropathy (excavation, diffuse or focal thinning or notching of the neuroretinal rim, visible nerve fiber layer defects, or asymmetry of the vertical cup-to-disc ratio of \>0.2 between eyes) \[enrollment of trial participants with High-risk OHT will be capped at 25% of total enrollment\]
- Mild primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation \>-6.0 dB with no points in the central 5° \<15 dB
- Moderate primary open-angle glaucoma: glaucomatous optic neuropathy, visual field mean deviation -6.0 dB to \>-12 dB and no more than 1 central 5° point \<15 dB
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MUSC Health West Ophthalmology Clinic Coordinator of this site? Confirm its status | Charleston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.